| mRNA |
OSI-930 |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
1e-05 |
| mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
2e-05 |
| mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
2e-05 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
2e-05 |
| mRNA |
narciclasine |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
2e-05 |
| mRNA |
AT13387 |
CTRPv2 |
pan-cancer |
AAC |
-0.21 |
2e-05 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
3e-05 |
| mRNA |
GSK1070916 |
GDSC1000 |
pan-cancer |
AAC |
-0.15 |
3e-05 |
| mRNA |
AR-42 |
GDSC1000 |
pan-cancer |
AAC |
-0.14 |
3e-05 |
| mRNA |
MK 1775 |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
3e-05 |